Henner Graeff

TL;DR: The number of invasive procedures is unlikely to be significantly reduced by PET imaging in patients presenting with abnormal mammography, however, the high positive-predictive value, resulting from the increased metabolic activity of malignant tissue, may be used with carefully selected subsets of patients as well as to determine the extent of disease or to assess therapy response.

TL;DR: The role of positron emission tomography using [18F]fluorodeoxyglucose (FDG) to monitor primary chemotherapy in patients with locally advanced breast cancer was addressed and significant differences in tracer uptake between nonresponding tumors and responding lesions were observed.

TL;DR: Using uPA and PAI-1, the Chemo N(0) prospective randomized multicenter therapy trial is able to classify about half of the patients with lymph node-negative breast cancer as low risk, for whom adjUvant chemotherapy may be avoided, and half as high risk, who appear to benefit from adjuvant chemotherapy.

TL;DR: The strong correlation between elevated uPA and/or PAI-1 values in primary cancer tissues and the tumor invasion/ metastasis capacity of cancer cells, proteolytic factors have been selected as targets for therapy.

TL;DR: Immunohistochemical staining of Rac1 showed weak Rac1 expression in benign breast disease but high expression level in ductal carcinoma-in-situ, primary breast cancer, and lymph node metastases, suggesting activation of Rac 1, in patients with aggressive breast cancer.